PURPOSE OF REVIEW: Reduce the burden of follow-up for patients and healthcare 
providers in noninvasive bladder cancer (NIBC). The evolution of intraoperative 
tumor detection, imaging modalities, urinary markers, and intravesical 
instillation regimens as a possibility to improve tumor eradication, enhance 
noninvasive tumor monitoring and thus to reduce costs is reviewed.
RECENT FINDINGS: On the basis of current evidence, the recurrence and 
progression of patients with NIBC can significantly be improved by 
fluorescence-guided transurethral resection and perioperative chemoinstillation. 
Virtual cystoscopic modalities based on computed tomography or magnetic 
resonance imaging as well as a combination of urine biomarkers, which improve 
the sensitivity of conventional urine cytology, has the potential to reduce 
discomfort and pain associated with conventional cystoscopy. Recent 
meta-analyses have furthermore demonstrated that risk-adapted instillation 
regimens for immediate, induction and maintenance therapy using 
immuno-instillation and chemoinstillation therapy improve significantly 
recurrence-free and progression-free survival rates.
SUMMARY: Emerging technologies in the field of tumor visualization in 
combination with urinary markers and effective instillation regimens can 
significantly reduce the risk of recurrence and progression in the long-term 
whilst providing less patient discomfort and simplifying the follow-up in 
patients of NIBC.